TYCC
ARCT icon

Texas Yale Capital Corp’s Arcturus Therapeutics ARCT Stock Holding History

Texas Yale Capital Corp’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$98.1K – 503
2025
Q4 		$98.1K Hold
16,000
– – ﹤0.01% 488
2025
Q3 		$295K Hold
16,000
– – 0.01% 419
2025
Q2 		$208K Hold
16,000
– – 0.01% 449
2025
Q1 		$169K Hold
16,000
– – 0.01% 438
2024
Q4 		$272K Hold
16,000
– – 0.01% 405
2024
Q3 		$371K Hold
16,000
– – 0.02% 363
2024
Q2 		$390K Buy
+16,000
New +$485K 0.02% 343

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Texas Yale Capital Corp's ARCT Position: Q1 2026 in Review

Texas Yale Capital Corp sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 16,000 shares — an estimated $98.1K sold.

Texas Yale Capital Corp first reported a position in ARCT in Q2 2024 and held it in 7 quarters. The position peaked at $390K in Q2 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Texas Yale Capital Corp reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Texas Yale Capital Corp sold 16,000 Arcturus Therapeutics shares in Q1 2026, an estimated $98.1K.
  • Texas Yale Capital Corp first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 7 quarters.
  • Texas Yale Capital Corp's Arcturus Therapeutics position peaked at $390K in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.